CTOs on the Move

Ra Medical

www.ramed.com

 
Advanced Excimer Laser-Based Vascular and Dermatological Therapies We are a medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients` quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. We currently manufacture and market two lines of products: DABRA Catheter and Laser is cleared by the U.S. FDA as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, including peripheral artery disease (PAD) and critical limb ischemia (CLI). Pharos Excimer Laser is FDA ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ramed.com
  • 2070 Las Palmas Drive
    Carlsbad, CA USA 92011
  • Phone: 760.804.1648

Executives

Name Title Contact Details

Similar Companies

The American Board of Physical Medicine and Rehabilitation

The American Board of Physical Medicine and Rehabilitation is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

H2O Plus

H2O Plus is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. H2O Plus is based in Chicago, IL. You can find more information on H2O Plus at www.h2oplus.com

Visiting Nurse Service

Visiting Nurse Service is a Northport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UnitedHealthcare

UnitedHealthcare offers health insurance plans to meet the needs of individuals and employers. Plus we offer dental, vision and many other insurance plans to help keep you and your family healthy.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic